DoD sharing its medical safety data with FDA

Share this article:
Data from the US Military Health System related to the review and use of FDA-regulated drugs, biologics and medical devices will be shared with the FDA to help safety reviews.

An FDA news release says general patient data such as prescriptions, lab results and patient weight will be used by FDA to spot trends that may identify potential concerns and recognize product benefits. The two organizations committed to protecting all personal health information exchanged under their partnership agreement.

The partnership is part of the FDA's Sentinel Network that is intended to explore linking private sector and public sector information to create an integrated electronic network. Among the DoD programs involved in the agreement is Tricare, the agency that administers the healthcare plan serving 9.1 million members of the uniformed services, retirees, and their families. Officials say Tricare Rx information is likely to be the first item shared.

Officials from the FDA and the DoD will meet later this year to establish guidelines.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?